<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819402</url>
  </required_header>
  <id_info>
    <org_study_id>PIO FAT</org_study_id>
    <nct_id>NCT01819402</nct_id>
  </id_info>
  <brief_title>Pioglitazone Decreases Visceral Fat Metabolism</brief_title>
  <official_title>Effects of Pioglitazone on Visceral Fat Metabolic Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kurume University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kurume University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excess visceral fat is associated with chronic systemic inflammation and cardiovascular
      complications. Pioglitazone has been reported to variably influence visceral fat volume, but
      it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate
      the effect of pioglitazone on glucose metabolism of fat tissue by using
      18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
      imaging.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of treatment on the nominal change in FDG uptake of fat tissue from baseline after 16 weeks of treatment as measured by FDG-PET/CT imaging.</measure>
    <time_frame>Baseline and 16 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma glucose/insulin homeostatic parameters and circulating inflammatory markers</measure>
    <time_frame>Baseline and 16 weeks after treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>All cardiovascular events and all cause death for 5 years</measure>
    <time_frame>Baseline and 5 years after treatment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging</condition>
  <arm_group>
    <arm_group_label>Active Comparator: 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>up to 30 mg pioglitazone, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator: 1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>up to 4 mg/day glimepiride, tablet, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone vs Glimepiride</intervention_name>
    <arm_group_label>Active Comparator: 1</arm_group_label>
    <arm_group_label>Sham Comparator: 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects between the ages of 35 and 85 years

          -  Subjects with impaired glucose tolerance and type 2 diabetes

        Exclusion Criteria:

          -  Subjects with insulin treatment

          -  Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery
             disease, symptomatic cerebrovascular disease

          -  Subjects taking more than three antidiabetic medications

          -  Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones within
             8 weeks prior to randomization

          -  Subjects with cardiac failure (New York Heart Association Class &gt; III) or left
             ventricular dysfunction (LVEF &lt; 40%)

          -  Subjects with systemic disorders such as active inflammatory, liver, renal,
             hematopoietic, and malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nobuhiro Tahara, MD, PhD</last_name>
    <phone>+81-942-31-7580</phone>
    <email>ntahara@med.kurume-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kurume University</name>
      <address>
        <city>Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuhiro Tahara, MD, PhD</last_name>
      <phone>+81-942-31-7580</phone>
      <email>ntahara@med.kurume-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2013</study_first_submitted>
  <study_first_submitted_qc>March 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>March 24, 2013</last_update_submitted>
  <last_update_submitted_qc>March 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kurume University</investigator_affiliation>
    <investigator_full_name>Nobuhiro Tahara</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>visceral fat metabolism; FDG-PET/CT; pioglitazone; glimepiride; adiponectin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

